Human placental collagen compositions, and methods of making and using the same

• US 9,770,488 B2
• Filed: 02/26/2013
• Issued: 09/26/2017
• Est. Priority Date: 10/06/2006
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Bhatia, Mohit, Lugo, Chris, Ye, Qian, Edinger, James W.
• Primary Examiner(s): AUDET, MAURY A
• Application Number:
  US13/777,391
• Publication Number:
  US 20130231288A1
• Time in Patent Office: 1,673 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/92 Oral administration
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 8/65 Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations
• CPC Class Codes: C07K 1/02 in solution C07K1/003, C07K1/006 take precedence
• CPC Class Codes: C07K 1/34 by filtration, ultrafiltration or reverse osmosis
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: G02B 2006/12147 Coupler
• CPC Class Codes: G02B 6/12004 Combinations of two or more optical elements
• CPC Class Codes: G02B 6/122 Basic optical elements, e.g. light-guiding paths
• CPC Class Codes: G02B 6/1228 Tapered waveguides, e.g. integrated spot-size transformers for coupling with fibres G02B6/305
• CPC Class Codes: G02B 6/124 Geodesic lenses or integrated gratings
• CPC Class Codes: G02B 6/2746 comprising non-reciprocal devices, e.g. isolators, FRM, circulators, quasi-isolators magneto-optic non-reciprocal devices G02F1/093
• CPC Class Codes: H01S 5/0064 Anti-reflection components, e.g. optical isolators
• CPC Class Codes: H01S 5/02326 Arrangements for relative positioning of laser diodes and optical components, e.g. grooves in the mount to fix optical fibres or lenses
• CPC Class Codes: H01S 5/026 Monolithically integrated components, e.g. waveguides, monitoring photo-detectors, drivers stabilisation of output H01S5/06
• CPC Class Codes: H01S 5/1032 : Coupling to elements comprising an optical axis that is not aligned with the optical axis of the active region
• CPC Class Codes: H01S 5/1035 : Forward coupled structures [DFC]
• CPC Class Codes: H01S 5/125 : Distributed Bragg reflector [DBR] lasers
• CPC Class Codes: H01S 5/187 : using Bragg reflection
• CPC Class Codes: H01S 5/2027 : Reflecting region or layer, parallel to the active layer, e.g. to modify propagation of the mode in the laser or to influence transverse modes
• CPC Class Codes: H01S 5/22 : having a ridge or stripe structure
• CPC Class Codes: H01S 5/3013 : AIIIBV compounds

Abstract

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

Claims

1. A method of treating a wound comprising contacting the wound with a composition comprising human placental extracellular matrix, wherein said human placental extracellular matrix comprises:

(i) placental collagen that comprises between 74% and 90% Type I collagen, between 4% to 6% Type III collagen, and between 2% to 15% type IV collagen, (ii) no detectable amounts of fibronectin or laminin, and (iii) additional extracellular matrix components selected from the following groups;

(a) 4.7% elastin by dry weight and 0.28% glycosaminoglycans by dry weight;

(b) 3.2% elastin by dry weight and 0.34% glycosaminoglycans by dry weight;

(c) 4.4% elastin by dry weight and 0.38% glycosaminoglycans by dry weight; and

(d) 3.5% elastin by dry weight and 0.59% glycosaminoglycans by dry weight.

2. The method of claim 1, wherein said composition is used as a wound filler.

3. The method of claim 1, wherein said composition is applied directly to the site of the wound.

4. The method of claim 1, wherein said composition is shaped to fit the site of the wound.

5. The method of claim 1, wherein said wound is a pressure ulcer, venous ulcer, diabetic ulcer, chronic vascular ulcer, tunneled wound, undermined wound, surgical wound, trauma wound, or draining wound.

6. The method of claim 1, wherein said wound is a leg ulcer.

7. The method of claim 6, wherein said leg ulcer is a venous leg ulcer, an arterial leg ulcer, a diabetic leg ulcer or a decubitus leg ulcer.

8. The method of claim 1, wherein said wound is a burn wound.

9. The method of claim 1, wherein said composition comprises an additional pharmacologically active agent.

10. The method of claim 9, wherein said additional pharmacologically active agent is platelet-derived growth factor, insulin-like growth factor, epidermal growth factor, transforming growth factor beta, an angiogenesis factor, an antibiotic, an antifungal agent, a hormone, an enzyme, or an enzyme inhibitor.

11. The method of claim 1, wherein the composition further comprises placental stem cells that are allogeneic to the subject.

12. The method of claim 1, wherein the composition further comprises placental stem cells that are autologous to the subject.